Argan, Inc. to Announce Second Quarter Fiscal 2027 Results and Host Conference Call on Wednesday, September 2, 2026 Business Wire Argan, Inc. (NYSE: AGX) (“Argan” or the “Company”) today announced that the Company will release its second quarter fiscal 2027 financial results after the market closes on Wednesday, September 2, 2026. Management will host a webcast with an accompanying slide presentation and conference call on Wednesday, September 2, 2026 at 5:00 p.m. ET. Participants can [...]
ReNew Announces Results for the First Quarter for Fiscal Year 2027 (Q1 FY27), Ended June 30, 2026 Business Wire ReNew Energy Global Plc (“ReNew”, “the Company”, “we” or “our”) (Nasdaq: RNW, RNWWW), a leading decarbonization solutions company, today announced its unaudited consolidated IFRS results for Q1 FY27. Operating Highlights: As of June 30, 2026, the Company’s portfolio consisted of ~20.5 GW (including 1.7 GW/6.2 GWh of BESS). Additionally, ReNew has 6.4 GW of solar [...]
Kolibri Global Energy Inc. Announces Another Record for Its Highest Quarterly Revenue of $22.5 Million With a 46% Production Increase and a 197% Net Income Increase for the Second Quarter of 2026 Business Wire All amounts are in U.S. Dollars unless otherwise indicated: SECOND QUARTER HIGHLIGHTS Revenue, net of royalties was $22.5 million in the second quarter of 2026 compared to $10.8 million for the second quarter of 2025, an increase of 109% due to a 46% increase in production and a 41% increase in average prices Average production [...]
Organigram Reports Record Third Quarter Fiscal 2026 Results August 11, 2026 Record Quarterly Revenue and Adjusted EBITDA(1) Driven by Acquisition of Sanity Group
Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results August 10, 2026 Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial and business results for the second quarter ended June 30, 2026. Business Highlights Divesiran: First-in-class siRNA silencing TMPRSS6 for polycythemia vera (PV) and other blood disorders Presented follow-up data from the Phase 1 SANRECO trial [...]
Algoma Central Corporation Reports Financial Results for the 2026 Second Quarter August 7, 2026 Strategic acquisitions, expanded credit facilities, and strong segment performance position Algoma for continued growth.
Allianz Delivers Record Result and Is Well on Track to Achieve Its Targets August 7, 2026 2Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806509750/en/ Total business volume at 45.6 billion euros, an internal growth of 5.7 percent1, with contributions from all segments. Asset Management delivers excellent growth. Operating profit rises 10.6 percent to a record level of 4.9 billion euros. Shareholders’ core net income at 2.6 [...]
Prothena Reports Second Quarter 2026 Financial Results and Business Highlights August 6, 2026 Net cash used in operating and investing activities was $25.7 million in the second quarter and net cash provided by operating and investing activities was $3.2 million for the first six months of 2026; quarter-end cash and restricted cash position was $289.1 million Guidance updated to include shares repurchased through July 30, 2026 and now expects to end the year with approximately $259 million (midpoint) in cash, cash equivalents and restricted cash Results from partner Roche evaluating prasinezumab in patients with early Parkinson’s disease from the Phase 2b PADOVA clinical trial published in The Lancet Multiple research collaborations with industry partners ongoing to explore the potential of our CYTOPE® technology over the next 12 to 24 months
eClerx Reports Strong Q1 FY2026-27 Results; Revenue Stands at INR 1,170.2 Crore, up 23.8% YoY August 5, 2026 eClerx Services Ltd (ECLERX.NS), a global leader in AI-powered analytics, digital operations, automation, and business process management, today announced its financial results for the quarter ended June 30, 2026. The company delivered a strong start to FY2026-27, reporting healthy growth in revenue and profitability, supported by disciplined execution, continued client demand and momentum across its [...]
Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights August 5, 2026 Data from two positive Phase 3 trials demonstrated rapid onset of effect and durable benefit through at least 6 months, further validating COMP360’s potential to establish a new standard of care in TRD COMP360 has a highly differentiated clinical profile and is expected to be a blockbuster opportunity, if approved Rolling NDA submission and initial review underway and final submission expected to be completed in Q4 Commercial launch expected in first half of 2027 COMP360 expected to fit seamlessly into current treatment infrastructure Late-stage PTSD trial underway Strong cash position of $433 million at the end of second quarter, providing cash well beyond launch and into 2028 Compass management will host a conference call on August 5 at 8:00 am ET